
**Arthroplasty Registry Analysis** 

## **Smith**Nephew

JOURNEY<sup>®</sup> II Bi-Cruciate Stabilised (BCS) OXINIUM<sup>®</sup> Total Knee System (TKS) demonstrates high long-term survivorship with lower revision risk versus other TKA implants in the AOANJRR<sup>1</sup>

- The AOANJRR annual report includes the revision rate for JOURNEY II BCS OXINIUM TKS both with and without patella resurfacing (6.3% at 5 years)<sup>2</sup>
- Data from the AOANJRR (up to January 2025) were obtained via the Automated Industry Report System (AIRS) to compare JOURNEY II BCS OXINIUM TKS
  versus all other TKAs when the patella was resurfaced<sup>1</sup>
- This independent analysis includes 10 years of data from 3,430 JOURNEY II BCS OXINIUM TKS procedures<sup>1</sup>
- Revision risk, expressed as a hazard ratio (HR), has been adjusted for variables such as age and gender<sup>1</sup>



## 10 years

98% survivorship for JOURNEY II BCS OXINIUM TKS when the patella is resurfaced1

Table 1. Yearly cumulative percent revision of primary TKA by model (all diagnoses). (Table 12, AOANJRR AIRS report 08/01/2025)

CPR	1 Yr	2 Yrs	3 Yr:	S	4 Yrs	5 Yrs
Journey II Oxinium/Journey	0.4 (0.2, 0.7)	0.8 (0.5,	1.3) 1.1	(0.7, 1.9)	2.0 (0.8, 4.9)	2.0 (0.8, 4.9)
Other Total Knee	0.9 (0.9, 0.9)	1.6 (1.5,	1.6) 2.1	(2.0, 2.1)	2.4 (2.4, 2.5)	2.7 (2.7, 2.8)
CPR	6 Yrs	7 Yrs	8 Yrs	9 Yrs	10 Yrs	11 Yrs
Journey II Oxinium/Journey	2.0 (0.8, 4.9)	2.0 (0.8, 4.9)	2.0 (0.8, 4.9)	2.0 (0.8, 4.9)	2.0 (0.8, 4.9)	
Other Total Knee	3.0 (3.0, 3.0)	3.3 (3.2, 3.3)	3.5 (3.5, 3.6)	3.8 (3.7, 3.9)	4.1 (4.0, 4.1)	4.4 (4.3, 4.4)
CPR	12 Yrs	13 Yrs	14 Yrs	15 Yrs	16 Yrs	17 Yrs
Journey II Oxinium/Journey						
Other Total Knee	4.7 (4.6, 4.7)	5.0 (4.9, 5.1)	5.3 (5.2, 5.4)	5.6 (5.5, 5.7)	6.0 (5.9, 6.1)	6.3 (6.2, 6.4)
CPR	18 Yrs	19 Yrs	20 Yrs	21 Yrs	22 Yrs	23 Yrs
Journey II Oxinium/Journey						
Other Total Knee	6.6 (6.5, 6.8)	6.9 (6.8, 7.1)	7.2 (7.1, 7.4)	7.5 (7.3, 7.7)	7.7 (7.5, 8.0)	7.8 (7.6, 8.1)

## Conclusion

At 10 years follow-up, JOURNEY II BCS OXINIUM TKS results in high survivorship and lower risk of revision than the average for other TKAs in the AOANJRR (both groups had patella resurfaced). $^{1}$ 

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use.

Abbreviations: AIRS = automated industry report system; AOANJRR = Australian Orthopaedic Association National Joint Replacement Registry; BCS = bi-cruciate stabilised; HR = hazard ratio.

References: 1. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), Automated Industry Report System (AIRS), ID No.16955\* for Smith & Nephew Australia, JOURNEY II OXINIUM Total Knee (Procedures from 1 September 1999 – 7 January 2025), Accessed 31 January 2025, report generated January 8, 2025, AOA, Adelaide: 1–16. 2. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee and Shoulder Arthroplasty: 2024 Annual Report, AOA, Adelaide; 2024:1–629. Available at: https://aoanjrr.sahmri.com/annual-reports-2024. Accessed 03 February 2025.

\*AOANJRR is confident in the accuracy of the data included in this report, at the time it was provided. However, it was generated using an automated reporting system and has not been reviewed by the AOANJRR personnel.